Hisamitsu Pharmaceutical Co., Inc. Overview
Pro stress-test →Hisamitsu Pharmaceutical manufactures and sells pharmaceuticals in Japan, specializing in the niche transdermal drug delivery system (TDS) market. The company is best known for its flagship over-the-counter brand Salonpas®, recognized as the world's No. 1 topical analgesic patch. It exports its products to Asia, the United States, and the European area.
Strategic Profile
Pro stress-test →The company operates a single business segment focusing on medical and general pharmaceuticals both in Japan and overseas, marketing drugs under the Salonpas, Nobinobi/Salonsip, Butenalock, and Mohrus brands, which mainly serve topical medication needs. As of February 19, 2026, Hisamitsu Pharmaceutical operates as a subsidiary of Taiyo Kosan Co., Ltd. The company maintains a strong position in OTC pain relief with established brand recognition globally.
Competitive Landscape
Pro stress-test →Hisamitsu competes in the topical medication market with brands like Salonpas, Nobinobi/Salonsip, Butenalock, and Mohrus. The company faces competition from global OTC pharmaceutical manufacturers and other topical pain relief product makers, though its Salonpas brand maintains market leadership in topical analgesics. The company's premium valuation reflects its established market position but faces headwinds from slow earnings growth forecasts.
Industry Context
Hisamitsu Pharmaceutical Co., Inc. operates in Pharmaceutical Manufacturing & OTC Healthcare Products.
Key facts
Founded: 1847 · Headquarters: Tosu, Japan · Revenue: ¥163.0B (FY 2026 trailing 12-month) · Market cap: ¥423.01B (~$2.67B USD, April 2026)